Pharmacodynamic and pharmacokinetic features of cabergoline: Rationale for use in Parkinson's diseaseFARIELLO, R. G.Drugs (Basel). 1998, Vol 55, pp 10-16, issn 0012-6667, SUP1Conference Paper

Lesson of the month (1): Cabergoline ― 'I eat funny on that'VIDATH SASANKA PREMARATNE; SAEGER, Ivan; MACDONALD, Bridget K et al.Clinical medicine. 2014, Vol 14, Num 2, pp 205-207, issn 1470-2118, 3 p.Article

The treatment with cabergoline for 24 months normalizes the quality of seminal fluid in hyperprolactinaemic malesDE ROSA, Michele; CICCARELLI, Antonio; ZARRILLI, Stefano et al.Clinical endocrinology (Oxford. Print). 2006, Vol 64, Num 3, pp 307-313, issn 0300-0664, 7 p.Article

Effective cabergoline treatment in idiopathic restless legs syndromeSTIASNY-KOLSTER, K; BENES, H; PEGLAU, I et al.Neurology. 2004, Vol 63, Num 12, pp 2272-2279, issn 0028-3878, 8 p.Article

Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonistPORTER, M-C; APPIAH-KUBI, L. S; CHAUDHURI, K. R et al.International journal of clinical practice (Esher). 2002, Vol 56, Num 6, pp 468-474, issn 1368-5031Article

Efficacy of cabergoline in restless legs syndrome : A placebo-controlled study with polysomnography (CATOR)OERTEL, W. H; BENES, H; STIASNY-KOLSTER, K et al.Neurology. 2006, Vol 67, Num 6, pp 1040-1046, issn 0028-3878, 7 p.Article

Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatmentELENKOVA, Atanaska; SHABANI, Rabhat; KALINOV, Krassimir et al.European journal of endocrinology. 2012, Vol 167, Num 1, pp 17-25, issn 0804-4643, 9 p.Article

No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinomaHALPERIN, Irene; ALLER, Javier; MIRELIS, Jesus G et al.Clinical endocrinology (Oxford. Print). 2012, Vol 77, Num 2, pp 275-280, issn 0300-0664, 6 p.Article

Physicochemical characterization of nicergoline and cabergoline in its amorphous stateMARTENA, Valentina; CENSI, Roberta; HOTI, Ela et al.Journal of thermal analysis and calorimetry. 2012, Vol 108, Num 1, pp 323-332, issn 1388-6150, 10 p.Article

Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomasPATHANASOULIA, A; SIEVERS, C; ISING, M et al.European journal of endocrinology. 2012, Vol 167, Num 3, pp 327-335, issn 0804-4643, 9 p.Article

Survey of lactation suppression in HIV-positive pregnant womenPAMMI, M; CARLIN, E. M.International journal of STD & AIDS. 2012, Vol 23, Num 4, pp 280-281, issn 0956-4624, 2 p.Article

Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patientsDELGRANGE, Etienne; DAEMS, Tania; VERHELST, Johan et al.European journal of endocrinology. 2009, Vol 160, Num 5, pp 747-752, issn 0804-4643, 6 p.Article

Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptorsCHAU, Kai-Yin; PRASAD KORLIPARA, L. V; COOPER, J. Mark et al.Journal of the neurological sciences. 2009, Vol 278, Num 1-2, pp 44-53, issn 0022-510X, 10 p.Article

Valvular heart disease and the use of cabergoline for the treatment of prolactinomaHERRING, Neil; SZMIGIELSKI, Cezary; BECHER, Harald et al.Clinical endocrinology (Oxford. Print). 2009, Vol 70, Num 1, pp 104-108, issn 0300-0664, 5 p.Article

Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural MalawiBUHENDWA, L; ZACHARIAH, R; TECK, R et al.Tropical doctor. 2008, Vol 38, Num 1, pp 30-32, issn 0049-4755, 3 p.Article

Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine : case report. CommentaryKAWABATA, Yasuhiro; UENO, Yasushi; HORIKAWA, Fumihiko et al.Surgical neurology. 2008, Vol 69, Num 1, pp 85-88, issn 0090-3019, 4 p.Article

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome : Results from a multicenter, randomized, active controlled trialTRENKWALDER, Claudia; BENES, Heike; GROTE, Ludger et al.Movement disorders. 2007, Vol 22, Num 5, pp 696-703, issn 0885-3185, 8 p.Article

Prise en charge du syndrome de Nelson : données actuelles = Nelson's syndrome management : current knowledgeGARCIA, C; BORDIER, L; GARCIA-HEJL, C et al.La Revue de médecine interne (Paris). 2007, Vol 28, Num 11, pp 766-769, issn 0248-8663, 4 p.Article

Cabergoline reverses cortical hyperexcitability in patients with restless legs syndromeNARDONE, R; AUSSERER, H; BRATTI, A et al.Acta neurologica scandinavica. 2006, Vol 114, Num 4, pp 244-249, issn 0001-6314, 6 p.Article

Efficacy and safety of high-dose cabergoline in Parkinson's diseaseODIN, P; OEHLWEIN, C; STORCH, A et al.Acta neurologica scandinavica. 2006, Vol 113, Num 1, pp 18-24, issn 0001-6314, 7 p.Article

Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. prompt response to medical treatmentSCARONE, Pietro; LOSA, Marco; MORTINI, Pietro et al.Journal of neuro-oncology. 2006, Vol 76, Num 1, pp 51-54, issn 0167-594X, 4 p.Article

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusCOZZI, Renato; ATTANASIO, Roberto; LODRINI, Sandro et al.Clinical endocrinology (Oxford. Print). 2004, Vol 61, Num 2, pp 209-215, issn 0300-0664, 7 p.Article

The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's diseaseHÖGL, Birgit; ROTHDACH, Andreas; WETTER, Thomas C et al.Neuropsychopharmacology (New York, NY). 2003, Vol 28, Num 10, pp 1866-1870, issn 0893-133X, 5 p.Article

The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinomaGILLAM, Mary P; MIDDLER, Stewart; FREED, Daniel J et al.The Journal of clinical endocrinology and metabolism. 2002, Vol 87, Num 10, pp 4447-4451, issn 0021-972XArticle

Le traitement des micro-adénomes à prolactine par cabergoline = The treatment of prolactin microadenomas with cabergolineBECKERS, A.Références en gynécologie obstétrique. 2001, Vol 8, Num 1, pp 28-31, issn 1244-8168Article